Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach?
Nissen
Steven E
SE
D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D023381:Endpoint Determination; D006538:Heptanoic Acids / Q000008:administration & dosage; D006760:Hospitalization; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D009204:Myocardial Revascularization; D017035:Pravastatin / Q000008:administration & dosage; D011758:Pyrroles / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D055502:Secondary Prevention; D020521:Stroke / Q000517:prevention & control; D013997:Time Factors
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D002784:Cholesterol; D000069059:Atorvastatin; D017035:Pravastatin